Actuate Therapeutics, Inc. Common stock (ACTU) Stock Price

ACTUStock
$1.5885.29%52W
Market Cap$37.94M
P/E
PEG Ratio
Div yield
Beta1.40

ACTU Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-82.30%
Price vs S&P 500 (4W)12.99%
VGM Score23.72

ACTU Earnings Surprise History

Q2 25-0.30est. -0.32
Q3 25-0.25est. -0.28
Q4 25-0.18est. -0.24
Q1 26-0.24est. -0.21
Q2 26-0.20est. -0.20

ACTU Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.10
4.10
4.10
4.10

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
ACTUActuate Therapeutics, Inc. Common stock
D$1.58
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Actuate Therapeutics, Inc. Common stock

Actuate Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies targeting GSK-3, a key regulator of tumor cell survival and growth. The company's lead candidate, elraglusib, is designed to inhibit GSK-3B and disrupt oncogenic signaling pathways in difficult-to-treat cancers. Actuate is pursuing a novel mechanism of action to address cancers with limited therapeutic options.